These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16467076)

  • 21. Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma.
    Weber J; Boswell W; Smith J; Hersh E; Snively J; Diaz M; Miles S; Liu X; Obrocea M; Qiu Z; Bot A
    J Immunother; 2008; 31(2):215-23. PubMed ID: 18481391
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Are vaccines making a comeback in non-small-cell lung cancer?
    Nemunaitis JJ
    J Clin Oncol; 2008 Mar; 26(9):1402-3. PubMed ID: 18349390
    [No Abstract]   [Full Text] [Related]  

  • 23. Melanoma vaccine candidates from chimeric hepatitis B core virus-like particles carrying a tumor-associated MAGE-3 epitope.
    Kazaks A; Balmaks R; Voronkova T; Ose V; Pumpens P
    Biotechnol J; 2008 Nov; 3(11):1429-36. PubMed ID: 18956370
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gene expression profiling and clinical outcome in melanoma: in search of novel prognostic factors.
    Winnepenninckx V; van den Oord JJ
    Expert Rev Anticancer Ther; 2007 Nov; 7(11):1611-31. PubMed ID: 18020928
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antigens for cancer immunotherapy.
    Neller MA; López JA; Schmidt CW
    Semin Immunol; 2008 Oct; 20(5):286-95. PubMed ID: 18951039
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer. Cancer immunotherapy is more than a numbers game.
    Offringa R
    Science; 2006 Oct; 314(5796):68-9. PubMed ID: 17023641
    [No Abstract]   [Full Text] [Related]  

  • 27. A Comparison of 3 tumor markers (MIA, TA90IC, S100B) in stage III melanoma patients.
    Faries MB; Gupta RK; Ye X; Lee C; Yee R; Leopoldo Z; Essner R; Foshag LJ; Elashoff D; Morton DL
    Cancer Invest; 2007 Aug; 25(5):285-93. PubMed ID: 17661202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current immunotherapeutic strategies in malignant melanoma.
    Agostino NM; Ali A; Nair SG; Mosca PJ
    Surg Oncol Clin N Am; 2007 Oct; 16(4):945-73, xi. PubMed ID: 18022553
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo anti-melanoma activities of the Melan-A/MART-1(101-115) T CD4+ cell peptide.
    Balasse E; Gatouillat G; Patigny D; Andry MC; Madoulet C
    Vaccine; 2009 Oct; 27(44):6107-9. PubMed ID: 19686694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer testis antigens: a novel target in lung cancer.
    Chiriva-Internati M; Pandey A; Saba R; Kim M; Saadeh C; Lukman T; Chiaramonte R; Jenkins M; Cobos E; Jumper C; Alalawi R
    Int Rev Immunol; 2012 Oct; 31(5):321-43. PubMed ID: 23083344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccines in lymphoma.
    Levy R
    Clin Adv Hematol Oncol; 2004 Jul; 2(7):424, 427. PubMed ID: 16163215
    [No Abstract]   [Full Text] [Related]  

  • 32. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targets of protective tumor immunity.
    Dranoff G
    Ann N Y Acad Sci; 2009 Sep; 1174():74-80. PubMed ID: 19769739
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccine therapy for melanoma: current status and future directions.
    Terando AM; Faries MB; Morton DL
    Vaccine; 2007 Sep; 25 Suppl 2():B4-16. PubMed ID: 17646038
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design.
    Ebert LM; Liu YC; Clements CS; Robson NC; Jackson HM; Markby JL; Dimopoulos N; Tan BS; Luescher IF; Davis ID; Rossjohn J; Cebon J; Purcell AW; Chen W
    Cancer Res; 2009 Feb; 69(3):1046-54. PubMed ID: 19176376
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma.
    Dudek AZ; Mescher MF; Okazaki I; Math VT; Luo X; Curtsinger JM; Miller JS
    Am J Clin Oncol; 2008 Apr; 31(2):173-81. PubMed ID: 18391603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dipeptidyl peptidase II is not a marker for progression in melanoma.
    Fröhlich E; Maier E; Mack AF; Garbe C
    J Dermatol Sci; 2009 Jan; 53(1):68-71. PubMed ID: 18823758
    [No Abstract]   [Full Text] [Related]  

  • 38. [Opportunities and defiance of therapeutic anti-tumoral vaccination].
    Coulie P
    Bull Mem Acad R Med Belg; 2007; 162(10-12):505-14. PubMed ID: 18557392
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Melanoma vaccines--they should work.
    Danson S; Lorigan P
    Ann Oncol; 2006 Apr; 17(4):539-41. PubMed ID: 16556849
    [No Abstract]   [Full Text] [Related]  

  • 40. Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues.
    Jaeger J; Koczan D; Thiesen HJ; Ibrahim SM; Gross G; Spang R; Kunz M
    Clin Cancer Res; 2007 Feb; 13(3):806-15. PubMed ID: 17289871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.